Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

NCT04477993 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2
SARS-CoV2

Interventions

DRUG: Janus Kinase Inhibitor (ruxolitinib)
OTHER: Placebo

Sponsor

Vanderson Geraldo Rocha